首頁 > 市場調查報告書 > 製藥

處方藥循環系統

市場調查報告書

商品編碼

1567138

利伐沙班市場：按適應症、按劑型、按患者類型、按分銷管道、按地區

Rivaroxaban Market, By Indication (Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism, and Others), By Formulation, By Patient Type, By Distribution Channel, By Geography

出版日期: 2024年08月30日 | 出版商:

Coherent Market Insights | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

利伐沙班的全球市場預計到2024年為1,672萬美元，預計到2031年將達到2,611萬美元，2024年至2031年的複合年成長率為6.6%。

報告範圍		報告詳情
基準年	2023年	2024年市場規模	1672萬美元
實際資料	2019年至2023年	預測期	從2024年到2031年
預測 2024-2031 年複合年成長率：	6.60%	2031年價值預測	2611萬美元

圖：2024 年利伐沙班市場佔有率（%），依地區分類

由於全球深層靜脈栓塞症和肺動脈栓塞盛行率不斷上升，利伐沙班的全球市場在過去十年中一直穩步成長。 Rivaroxaban 是一種口服抗凝血劑，可作為凝血途徑中 Xa 因子的抑制劑。利伐沙班在需要抗凝血治療的患者中用作Warfarin的抗凝血替代品。此藥最常用於降低非瓣膜性心房顫動患者發生中風和全身性栓塞的風險，治療深層靜脈栓塞症和肺動脈栓塞，以及預防靜脈血栓栓塞症的復發。隨著人們對新型口服抗凝血劑益處的認知不斷提高，以及受目標疾病影響的患者數量不斷增加，利伐沙班市場預計在未來幾年將繼續快速擴張。

市場動態：

全球利伐沙班市場成長的驅動力是老年人口的增加，老年人口更容易發生血栓性栓塞症，相對於Warfarin等傳統藥物，人們對新型口服抗凝血劑的偏好日益增加，這是外科手術的增加。然而，與學名藥相比，利伐沙班治療的高昂成本是限制其廣泛使用的主要因素。從積極的一面來看，臨床試驗正在進行中，以評估利伐沙班的其他適應症，新年齡層的核准預計將創造新的機會。此外，開發適合特定患者類型的改良劑型可能有助於克服高成本帶來的挑戰。

本研究的主要特點

本報告對全球利伐沙班市場進行了詳細分析，並提出了以2023年為基準年的預測期（2024-2031）的市場規模和年複合成長率（CAGR%）。
它還揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的主要考察。
基於公司亮點、產品系列、主要亮點、財務表現和策略等參數的全球利伐沙班市場的主要企業概況。
該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球利伐沙班市場報告針對該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過分析全球利伐沙班市場時所使用的各種策略矩陣，將有助於相關人員做出決策。

北美洲
美國
加拿大
拉丁美洲
巴西
阿根廷
墨西哥
其他拉丁美洲
歐洲
德國
英國
西班牙
法國
義大利
俄羅斯
其他歐洲國家
亞太地區
中國
印度
日本
澳洲
韓國
ASEAN
其他亞太地區
中東
海灣合作理事會國家
以色列
其他中東地區
非洲
南非
北非
中部非洲

第9章競爭格局

Bayer AG
Janssen Pharmaceuticals, Inc.
Interquim SA
Natco Pharma
Mylan NV
Sandoz（a Novartis division）
Teva Pharmaceutical Industries Ltd.
Aurobindo Pharma
Zydus Cadila
Apotex Inc.
Hetero Labs Limited
Fresenius Kabi AG
Sun Pharmaceutical Industries Ltd.
Lupin Pharmaceuticals
Reddy's Laboratories
Bristol-Myers Squibb
Merck & Co., Inc.
Pfizer Inc.
Eisai Co., Ltd.
Amgen Inc.

第10章分析師建議

命運之輪
分析師觀點
一致的機會圖

第11章參考文獻與調查方法

參考
調查方法
關於出版商

簡介目錄

Product Code: CMI1962

Global Rivaroxaban Market is estimated to be valued at USD 16.72 Mn in 2024 and is expected to reach USD 26.11 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.6% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 16.72 Mn
Historical Data for:	2019 To 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	6.60%	2031 Value Projection:	US$ 26.11 Mn

Figure. Rivaroxaban Market Share (%), By Region, 2024

The global Rivaroxaban market has been growing steadily over the past decade on the back of rising prevalence of deep vein thrombosis and pulmonary embolism disorders globally. Rivaroxaban is an oral anticoagulant that acts as an inhibitor of factor Xa in the blood coagulation pathway. It has emerged as a preferred alternative to warfarin for patients requiring anticoagulation therapy due to advantages such as fixed dosing without need for frequent monitoring. The drug is most commonly used to reduce risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treat deep vein thrombosis and pulmonary embolism, and reduce recurrence of venous thromboembolism. With growing awareness about benefits of novel oral anticoagulants and increasing patient pool affected by target diseases, the rivaroxaban market is anticipated to continue expanding rapidly over the coming years.

Market Dynamics:

The global rivaroxaban market growth is driven by rising geriatric population who are more prone to thromboembolic disorders, growing preference for novel oral anticoagulants over traditional drugs like warfarin, and increasing number of surgical procedures performed worldwide. However, high costs associated with rivaroxaban therapy compared to generic drugs is a major factor limiting its widespread adoption. On the positive side, ongoing clinical trials evaluating rivaroxaban for additional indications and approval for new age groups are expected to create new opportunities. Moreover, development of modified dosage forms suited for specific patient types could help overcome challenges posed by high costs.

Key features of the study:

This report provides in-depth analysis of the global rivaroxaban market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global rivaroxaban market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Johnson & Johnson, Pfizer, Bayer, and Sanofi
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global rivaroxaban market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global rivaroxaban market.

Detailed Segmentation:

By Indication Insights (Revenue, USD Mn, 2019 - 2031)
- Atrial Fibrillation
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Prophylaxis of Venous Thromboembolism (VTE)
- Others (Acute Coronary Syndrome, etc.)
By Formulation Insights (Revenue, USD Mn, 2019 - 2031)
- Tablets
- Suspension
By Patient Type Insights (Revenue, USD Mn, 2019 - 2031)
- Adults
- Pediatrics
By Distribution Channel Insights (Revenue, USD Mn, 2019 - 2031)
- Hospitals and Clinics
- Retail Pharmacies
- Online Pharmacies
By Regional Insights (Revenue, USD Mn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Bayer AG
- Janssen Pharmaceuticals, Inc.
- Interquim SA
- Natco Pharma
- Mylan N.V.
- Sandoz (a Novartis division)
- Teva Pharmaceutical Industries Ltd.
- Aurobindo Pharma
- Zydus Cadila
- Apotex Inc.
- Hetero Labs Limited
- Fresenius Kabi AG
- Sun Pharmaceutical Industries Ltd.
- Lupin Pharmaceuticals
- Reddy's Laboratories
- Bristol-Myers Squibb
- Merck & Co., Inc.
- Pfizer Inc.
- Eisai Co., Ltd.
- Amgen Inc.

1. RESEARCH OBJECTIVES AND ASSUMPTIONS

Research Objectives
Assumptions
Abbreviations

2. MARKET PURVIEW

Report Description
- Market Definition and Scope
Executive Summary
- Global Rivaroxaban Market, By Indication
- Global Rivaroxaban Market, By Formulation
- Global Rivaroxaban Market, By Patient Type
- Global Rivaroxaban Market, By Distribution Channel
- Global Rivaroxaban Market, By Region

3. MARKET DYNAMICS, REGULATIONS, AND TRENDS ANALYSIS

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Rivaroxaban Market, By Indication, 2024-2031, (USD Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Atrial Fibrillation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Deep Vein Thrombosis (DVT)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Pulmonary Embolism (PE)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Prophylaxis of Venous Thromboembolism (VTE)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Others (Acute Coronary Syndrome, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

5. Global Rivaroxaban Market, By Formulation, 2024-2031, (USD Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Suspension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

6. Global Rivaroxaban Market, By Patient Type, 2024-2031, (USD Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Pediatrics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

7. Global Rivaroxaban Market, By Distribution Channel, 2024-2031, (USD Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

8. Global Rivaroxaban Market, By Region, 2019 - 2031, Value (USD Mn)

Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2019 - 2031, Value (USD Mn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Indication, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Formulation, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, By Indication, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Formulation, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
Brazil
Argentina
Mexico
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Indication, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Formulation, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Formulation, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Indication, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Formulation, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
GCC Countries
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Indication, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Formulation, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
South Africa
North Africa
Central Africa

9. COMPETITIVE LANDSCAPE

Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Janssen Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Interquim SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Natco Pharma
Mylan N.V.
Sandoz (a Novartis division)
Teva Pharmaceutical Industries Ltd.
Aurobindo Pharma
Zydus Cadila
Apotex Inc.
Hetero Labs Limited
Fresenius Kabi AG
Sun Pharmaceutical Industries Ltd.
Lupin Pharmaceuticals
Reddy's Laboratories
Bristol-Myers Squibb
Merck & Co., Inc.
Pfizer Inc.
Eisai Co., Ltd.
Amgen Inc.